ArticleJournal of the International AIDS Society2026
Cost-effectiveness of leveraging long-acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities.
Jesse A Heitner et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.